Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Great Point Partners and Adamas Pharmaceuticals Inc (ADMS)

Page 1 of 8

Adamas Pharmaceuticals Inc (NASDAQ:ADMS): Jeffrey Jay And David Kroin’s Great Point Partners filed an amended 13D.

You can check out Great Point Partners’s latest holdings and filings here.

Please follow Great Point Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Great Point Partners or update its stock holdings.

Jeffrey Jay And David Kroin
Jeffrey Jay And David Kroin
Great Point Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Great Point Partners 0 256,340 0 256,340 256,340 1.14%
Dr. Jeffrey R. Jay, M.D 0 256,340 0 256,340 256,340 1.14%
Mr. David Kroin 0 256,340 0 256,340 256,340 1.14%
Jeffrey Jay And David Kroin
Jeffrey Jay And David Kroin
Great Point Partners

Page 1 of 8 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Schedule 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

Adamas Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00548A106

(CUSIP Number)

September 30, 2017

(Date of Event which Requires Filing of this
Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:

x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)

*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Persons who respond to the collection
of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Follow Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Trade (NASDAQ:ADMS) Now!
Page 1 of 8